The possibility of intercepting inflammatory bowel disease years before a patient ever experiences symptoms has long been a clinical ambition — and this study from Gut moves that goal closer to reality. By mapping how the immune system quietly shifts long before Crohn's disease or ulcerative colitis is diagnosed, this research challenges the assumption that IBD emerges abruptly and opens a plausible window for preventive intervention.
Using phage-display immunoprecipitation sequencing (PhIP-Seq), researchers profiled antibody repertoires across 2,000 longitudinal serum samples drawn from 400 individuals who later developed IBD — 200 Crohn's disease and 200 ulcerative colitis cases — and 100 matched healthy controls, all drawn from the US military's PREDICTS cohort with samples collected up to a decade before diagnosis. Against a library of 357,000 peptides spanning microbial, viral, food, and immune-related antigens, the analysis revealed that antibody repertoire variability increased approximately four years before diagnosis in both Crohn's and UC. Elevated responses to herpesviruses — especially Epstein-Barr virus — and to anti-flagellin antigens appeared as early as ten years before Crohn's diagnosis, with the strongest signals in those who later developed complicated or ileal disease. Meanwhile, antibody responses to encapsulated bacteria such as Streptococcus pneumoniae progressively declined as diagnosis approached.
These findings are noteworthy for several reasons. The EBV association reinforces a growing body of literature implicating latent viral reactivation in autoimmune and immune-mediated disease, paralleling recent findings in multiple sclerosis. Anti-flagellin antibodies have long been associated with Crohn's pathophysiology, but their appearance a decade prediagnosis reframes them as potential early biomarkers rather than disease-state markers. The decline in responses to encapsulated bacteria suggests a selective immunological narrowing that may precede overt intestinal inflammation. The military cohort provides unusually clean longitudinal samples and precise diagnosis timing, but the population skews male, younger, and physically active — meaningful constraints on generalizability. This study is observational and cannot establish causation; whether these immune shifts drive IBD or merely accompany early subclinical disease remains unresolved. Still, the granularity of the antibody atlas produced here is paradigm-relevant for future early-interception trial design.